For research teamsHelp me find a study
Back to all studies
Not recruitingEUCTR 2021-003600-41

AMIloride for the treatment of Nephrogenic Diabetes insipidus for patients with Bipolarity treated with lithium: a randomized controlled trial

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

BipolarityDrugFrom 18 Years to 70 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What the source confirms

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

What should you check before joining?

Check the official protocol for eligibility, treatment, visits and assessments. If recruitment is listed, confirm with the team that a specific centre is still accepting participants before taking any next step.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View the historical EU CTR record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: January 11, 2023
Recruitment status
Not recruiting
Enrollment listed in the registry
Not clearly listed
Sponsor
Assistance Publique – Hôpitaux de Paris (AP-HP)
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
France
Age range
From 18 Years to 70 Years
Official registry ID
EUCTR 2021-003600-41
Official title
AMIloride for the treatment of Nephrogenic Diabetes insipidus for patients with bipolar disorder treated with lithium: a randomized controlled trial

Check recruitment and locations

EU CTR and CTIS records checked by HopeStage on . Registry information can change. Always confirm availability with the research team.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

View the historical EU CTR record (opens in a new tab)View the current CTIS record (opens in a new tab)
Current CTIS country statuses
Historical EU CTR country statuses
  • France : Trial now transitioned

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

France · 7 sites
  • Assistance Publique Hopitaux De Paris — Service de psychiatrie et addictologie
    Colombes Cedex
    Country status: Not recruiting
  • Assistance Publique Hopitaux De Paris — Centre expert Troubles bipolaires
    Creteil
    Country status: Not recruiting
  • Assistance Publique Hopitaux De Paris — Service de Néphrologie
    Creteil Cedex
    Country status: Not recruiting
  • Assistance Publique Hopitaux De Paris — Service de Psychiatrie et addictologie
    Creteil Cedex
    Country status: Not recruiting
  • Assistance Publique Hopitaux De Paris — Département de psychiatrie et de médecine addictologique
    Paris
    Country status: Not recruiting
  • Assistance Publique Hopitaux De Paris — Service de Néphrologie
    Paris Cedex 18
    Country status: Not recruiting
  • Assistance Publique Hopitaux De Paris — Service de Physiologie Explorations fonctionnelles multidisciplinaires
    Paris Cedex 18
    Country status: Not recruiting

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: EUCTR 2021-003600-41. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What does the official source confirm?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Is this study recruiting?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

How can I check the participation requirements?

Check the official protocol for the criteria, treatment and planned assessments. The research team must confirm visits, risks, open centres and your eligibility.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
Not recruitingEUCTR 2009-016648-38

A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With ...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Drug study icon
Not recruitingEUCTR 2005-004391-21

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Drug study icon
Not recruitingEUCTR 2007-002551-17

Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo i...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.